(74 days)
The intended use of this panel is for determining quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of Haemophilus spp.
After incubation in a non-CO2 incubator for 20 - 24 hours, the minimum inhibitory concentration (MIC) for the test organism is determined by observing the lowest antimicrobial concentration showing inhibition of growth.
The two-fold dilutions of AMPICILLIN in the panel range from 0.015 to 16 mcg/ml for testing Haemophilus spp.
Microdilution Minimum Inhibitory Concentration (MIC) Panels
Here's an analysis of the provided text regarding the acceptance criteria and study for the Dade MicroScan Inc. MicroScan® MICroSTREP plus™ Panel - Ampicillin:
1. Table of Acceptance Criteria and Reported Device Performance:
| Acceptance Criteria Category | Specific Metric / Requirement | Reported Device Performance |
|---|---|---|
| Performance | Overall Essential Agreement with NCCLS frozen Reference | 91.5% |
| Reproducibility | Acceptable results (implied by statement "Reproducibility testing demonstrated acceptable results") | Acceptable results |
| Quality Control | Acceptable results (implied by statement "Quality Control testing demonstrated acceptable results") | Acceptable results |
2. Sample Size Used for the Test Set and Data Provenance:
- Sample Size for Test Set: Not explicitly stated as a single number. The study used "fresh and stock Efficacy isolates and stock Challenge strains of Haemophilus spp." The total number of isolates tested is not provided in this summary.
- Data Provenance: Not explicitly stated, but it was an "external evaluation." The country of origin is not mentioned, and it is a prospective evaluation aimed at confirming performance.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications:
- Number of Experts: Not specified.
- Qualifications of Experts: Not specified.
- Adjudication Method: Not specified.
4. Adjudication Method for the Test Set:
- The document does not specify any adjudication method (e.g., 2+1, 3+1).
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done:
- No, an MRMC comparative effectiveness study was not done. This device is a diagnostic panel for susceptibility testing, not an imaging or interpretive device that typically involves human readers. The comparison was between the device and a reference method.
6. If a Standalone (algorithm only without human-in-the-loop performance) was done:
- Yes, this was a standalone performance study. The device, a microdilution panel, directly outputs a Minimum Inhibitory Concentration (MIC) value, which is then compared to a reference standard. There isn't an "algorithm only" in the sense of a software-based AI, but rather the performance of the physical test panel itself determining the MIC. Human technicians would "read" the panel, but the performance evaluation is of the panel's result against the reference.
7. The Type of Ground Truth Used:
- The ground truth used was an NCCLS frozen Reference, which serves as the gold standard for antimicrobial susceptibility testing.
8. The Sample Size for the Training Set:
- The document does not mention a "training set" as this is not an AI/machine learning device that requires training data in that sense. The device's performance is evaluated against a reference standard in a verification study.
9. How the Ground Truth for the Training Set was Established:
- Not applicable as there is no "training set" in the context of this device's development or evaluation as described. The "ground truth" for the evaluation set was the NCCLS frozen Reference.
{0}------------------------------------------------
K993679
JAN 1 4 2000
510(k) Summary Information:
| Device Manufacturer: Dade MicroScan Inc. | |
|---|---|
| Contact name: | Trevor Wall, Regulatory Affairs Manager |
| Fax: | 916-374-3144 |
| Phone: | 916-374-3332 |
| Date prepared: | October 20, 1999 |
| Product Name: | Microdilution Minimum Inhibitory Concentration (MIC) Panels |
| Trade Name: | MicroScan® MICroSTREP plus™ Panel - Ampicillin |
| Intended Use: | To determine bacterial susceptibility to AMPICILLIN |
| Indication for Use: | For use with Haemophilus spp. |
| Predicate device: | MicroScan® Streptococcus MIC Panel (K963641). |
510(k) Summary:
The proposed MicroScan® MICroSTREP plus™ : AMPICILLIN, demonstrated substantially equivalent performance with Haemophilus isolates when compared with an NCCLS frozen Reference, as defined in the FDA DRAFT document "Review Criteria for Assessment of Antimicrobial Susceptibility Devices" (dated May 31, 1991).
The Premarket Notification (510[k]) presents data in support of the new MICroSTREP plus™ Panel with AMPICILLIN ( 0.015 to 16 mcg/ml).
The external evaluation was conducted with fresh and stock Efficacy isolates and stock Challenge strains of Haemophilus spp. The external evaluations were designed to confirm the acceptability of the proposed MICroSTREP plus™ Panel - AMPICILLIN, by comparing its performance with an NCCLS frozen Reference. The MICroSTREP plus™ Panel - AMPICILLIN demonstrated acceptable performance with an overall Essential Agreement of 91.5% when compared with the frozen Reference Panel.
Reproducibility testing demonstrated acceptable results with AMPICILLIN.
Quality Control testing demonstrated acceptable results with AMPICILLIN.
{1}------------------------------------------------
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized image of an eagle with three lines forming its body and head. The logo is surrounded by text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" in a circular arrangement.
JAN 1 4 2000
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Mr. Trevor Wall Regulatory Affairs Manager Dade MicroScan, Inc. 1584 Enterprise Boulevard West Sacramento, California 95691
Re: K993679
Trade Name: MicroScan® MICroSTREP plus™ Panel (Haemophilus/Ampicillin) Regulatory Class: II Product Code: JWY Dated: October 29, 1999 Received: November 1, 1999
Dear Mr. Wall:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{2}------------------------------------------------
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{3}------------------------------------------------
Page of
510(k) Number (if known):_K99 3679
Device Name: MicroScau MicroScau Micro STREA plus
Indications For Use:
The intended use of this panel is for determining quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of Haemophilus spp.
After incubation in a non-CO2 incubator for 20 - 24 hours, the minimum inhibitory concentration (MIC) for the test organism is determined by observing the lowest antimicrobial concentration showing inhibition of growth.
The two-fold dilutions of AMPICILLIN in the panel range from 0.015 to 16 mcg/ml for testing Haemophilus spp.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Wooley Dubocs
ion of Clinical Laboratory Devices 4611 510(k) Number
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).